RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

<<Chief Executive Roger Stoll announced the company was in negotiations with at least eight big pharmaceutical companies that wanted to license CX717. Such a deal, Stoll said, would be worth immediately as much as $30 million to the company and eventually several hundred million dollars.>>

Having researched the 'figures' provided by Stoll from two years ago, the 30mill became 50mill (upfronts for ADHD). That enticing and enhanced number was given at a CC between a PIPE and the ADHD rejection. I guess he was talking post IND approval, but still....